(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

CANCERLINQ

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

CANCERLINQ

ST13

US500000085978639

Class

42

Filing

85978639

Registration

4960585

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

69

Latest update

05/19/2026

Trademark type

Word

Nice classes

42

Filing date

01/25/2012

Registration date

05/17/2016

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

04/28/2026

Last transaction

05/19/2026

Responsible office

United States Patent and Trademark Office

Status code

800

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

03/18/2016

First use in commerce

03/18/2016

Drawing code

4

Owner type

16

Owner location

CAMBRIDGE, MA, US

Examiner

MONINGHOFF, KIM TERESA

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

CANCERLINQ LLC
American Society of Clinical Oncology, Inc.

Representatives

Christopher A. Proskey BROWNWINICK LAW FIRM

Technical classification

Nice Classes

Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 42

Application service provider featuring software for use in aggregating and analyzing health care and medical data; conducting quality assurance assessment to improve the quality of cancer care; providing quality assurance services in the field of healthcarecollectingcomparinganalyzing of patient-level medical and clinical healthcare quality data for the purpose of analyzing the quality of cancer care and treatment

Publications

History of USPTO decisions and trademark events.

69 publications found

NA89

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED

04/28/2026

RNL1

REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)

04/28/2026

89AG

REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED

04/28/2026

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

04/28/2026

E89R

TEAS SECTION 8 & 9 RECEIVED

02/20/2026

REM2

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

05/17/2025

EWAF

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS

05/07/2025

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

05/07/2025

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

05/07/2025

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

05/07/2025

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

05/07/2025

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

05/07/2025

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

01/31/2024

NA85

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED

11/26/2021

C15A

REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

11/26/2021

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

11/26/2021

E815

TEAS SECTION 8 & 15 RECEIVED

08/24/2021

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

05/17/2021

R.PR

REGISTERED-PRINCIPAL REGISTER

05/17/2016

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

04/12/2016

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

04/11/2016

SUPC

STATEMENT OF USE PROCESSING COMPLETE

04/10/2016

IUAF

USE AMENDMENT FILED

04/06/2016

EISU

TEAS STATEMENT OF USE RECEIVED

04/06/2016

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

01/14/2016

EX5G

SOU EXTENSION 5 GRANTED

01/13/2016

EXT5

SOU EXTENSION 5 FILED

11/17/2015

EEXT

SOU TEAS EXTENSION RECEIVED

11/17/2015

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

05/23/2015

EX4G

SOU EXTENSION 4 GRANTED

05/22/2015

EXT4

SOU EXTENSION 4 FILED

05/11/2015

EEXT

SOU TEAS EXTENSION RECEIVED

05/11/2015

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

12/18/2014

EX3G

SOU EXTENSION 3 GRANTED

12/17/2014

EXT3

SOU EXTENSION 3 FILED

11/12/2014

EEXT

SOU TEAS EXTENSION RECEIVED

11/12/2014

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

05/29/2014

EX2G

SOU EXTENSION 2 GRANTED

05/28/2014

EXT2

SOU EXTENSION 2 FILED

05/19/2014

EEXT

SOU TEAS EXTENSION RECEIVED

05/19/2014

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

11/19/2013

EX1G

SOU EXTENSION 1 GRANTED

11/18/2013

EXT1

SOU EXTENSION 1 FILED

11/12/2013

EEXT

SOU TEAS EXTENSION RECEIVED

11/12/2013

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

05/21/2013

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

03/26/2013

PUBO

PUBLISHED FOR OPPOSITION

03/26/2013

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

03/06/2013

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

02/21/2013

MPMK

NOTICE OF PSEUDO MARK E-MAILED

02/20/2013

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

02/19/2013

DPCC

DIVISIONAL PROCESSING COMPLETE

02/19/2013

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

02/13/2013

DRRR

DIVISIONAL REQUEST RECEIVED

01/29/2013

ERTD

TEAS REQUEST TO DIVIDE RECEIVED

01/29/2013

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

11/29/2012

GNSL

LETTER OF SUSPENSION E-MAILED

11/29/2012

CNSL

SUSPENSION LETTER WRITTEN

11/29/2012

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

11/21/2012

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

11/21/2012

ALIE

ASSIGNED TO LIE

11/16/2012

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

11/08/2012

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

05/08/2012

GNRT

NON-FINAL ACTION E-MAILED

05/08/2012

CNRT

NON-FINAL ACTION WRITTEN

05/08/2012

DOCK

ASSIGNED TO EXAMINER

05/03/2012

MPMK

NOTICE OF PSEUDO MARK MAILED

01/31/2012

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

01/28/2012

NWAP

NEW APPLICATION ENTERED

01/28/2012

Continuous trademark protection

Get notified about every new filing that threatens CANCERLINQ or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.